<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397199</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HNP052</org_study_id>
    <nct_id>NCT03397199</nct_id>
  </id_info>
  <brief_title>Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase II Clinical Trial of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the
      Therapy of Advanced Colorectal Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer is a common clinical gastrointestinal cancer. In addition to the early
      diagnosis of some patients, approximately 50% of patients have had distant metastases at the
      time of diagnosis. For patients with advanced colorectal cancer, systemic chemotherapy is the
      main treatment. We consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the
      therapy of these patients. We designed the study to explore the possibility of apatinib for
      Advanced Colorectal Cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR
+ PR + SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib + S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib + S-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib + S-1</intervention_name>
    <description>Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA &lt;1.4, 60mg bid BSA&gt;1.4），bid,from day1-day 14.</description>
    <arm_group_label>Apatinib + S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed the informed consent form prior to patient entry.

          2. Histologically or cytologically diagnosed as metastatic colon or rectal adenocarcinoma
             patients.

          3. The second-line standard regimen failed (disease progression) and the chemotherapy
             regimen included fluorouracil (5-FU / capecitabine / tioguanide), oxaliplatin and
             irinotecan from the last chemotherapy&gt; 14 days.

          4. ≥ 18 and ≤ 70 years of age.

          5. Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.

          6. Life expectancy of more than 3 months.

          7. According to the solid tumor efficacy evaluation criteria RECISTv1.1 standards, at
             least one measurable lesions. If the previous treatment of local treatment
             (radiotherapy, radiofrequency, intervention, etc.) is the only focus of lesions, the
             request must have a clear imaging progress.

          8. Adequate hepatic, renal, heart, and hematologic functions: ANC ≥1.5×109/L, PLT ≥
             100×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST≤ 2.5×ULN (or ≤ 5×ULN in patients
             with liver metastases), Serum Cr≤ 1.5×ULN, Cr clearance ≥ 60 mL/min.

          9. Female subjects of child-bearing potential must agree to use contraceptive measures
             starting 1 week before the administration of the first dose of apatinib until 6 months
             after discontinuing study drug. Male subjects must agree to use contraceptive measures
             during the study and 6 months after last dose of study drug.

        Exclusion Criteria:

          1. Uncontrollable hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, despite
             optimal medical therapy).

          2. Poor glycemic control in diabetes.

          3. Acute cerebral infarction, or recovery period &lt;2 months.

          4. A variety of factors that affect oral absorption (such as inability to swallow,
             nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).

          5. Patients with gastrointestinal bleeding risk may not be included, including the
             following: (1) active peptic ulcer lesions and fecal occult blood (++); (2) history of
             melena and vomiting within 3 months；Fecal occult blood (+) is not an exclusion
             criterion.

          6. Coagulation dysfunction (INR&gt; 1.5, PT&gt; ULN + 4s or APTT&gt; 1.5 ULN), with bleeding
             tendency or ongoing thrombolysis or anti-blood coagulation treatment.

          7. Patients whose routine urine tests indicate that urine protein ≥ ++ or verifies that
             the 24-h urine protein quantitation ≥ 1.0 g.

          8. Pregnant or lactating women.

          9. Cytotoxic drug treatment, radiotherapy within 2 weeks after treatment; had taken two
             or more oral targeted drugs.

         10. Other malignant tumors, cutaneous basal cell carcinoma, and cervical cancer in situ in
             the past 5 years.

         11. The investigators believe there is any condition that may harm the subject or result
             in the subject's inability to meet or perform the research requirements

         12. Severe liver and kidney dysfunction (grade 4) patients should be excluded.

         13. Any allergy to apatinib should be excluded.

         14. Persons with a history of substance abuse who can not be abdicated or have mental
             disorders.

         15. Previously used regurgitine is not an exclusion criterion.

         16. According to the judgment of the researcher, there is a concomitant disease that
             seriously endangers the patient's safety or affects the patient in completing the
             study.

         17. Patients who underwent surgery within 4 weeks prior to the start of treatment or who
             had major trauma or fractures. Or there is an unhealed wound before treatment.

         18. Patients with severe heart disease such as grade III or above (NYHA standard)
             congestive heart failure, grade III or above (CCS standard) angina, or a history of
             myocardial infarction within 6 months prior to the start of treatment, or patients
             requiring medication Arrhythmia.

         19. A brain metastasis, meningeal transfer.

         20. Active HBV infection and refusal of regular antiviral treatment.

         21. Active tuberculosis patients.

         22. Participate in any drug or medical device clinical trial within 1 month before the
             test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suxia Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ning Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Li</last_name>
    <phone>13526501903</phone>
    <email>lining97@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

